Table 3.

Median Trough Edoxaban Drug Concentration and Factor Xa Activity by Treatment Regimen and Malignancy Status at Day 29

Treatment Regimen and Dose
HDER (60 mg)			HDER‐DR (30 mg)			LDER (30 mg)			LDER‐DR (15 mg)
Cancer	No Cancer	P Value	Cancer	No Cancer	P Value	Cancer	No Cancer	P Value	Cancer	No Cancer	P Value
Edoxaban concentration, trough level at day 29, median (interquartile range), ng/mL
38.4 (23.1–55.8)	35.9 (19.1–61.9)	0.57	22.9 (13.9–44.0)	28.2 (15.1–46.6)	0.40	17 (9.9–31.6)	18.4 (10.0–32.4)	0.44	11.1 (8.7–17.0)	12.8 (7.3–21.6)	0.95
Factor Xa activity, trough level at day 29, median (interquartile range), IU/mL
0.79 (0.49–1.16)	0.63 (0.37–1.10)	0.25	0.52 (0.29–0.94)	0.52 (0.31–0.84)	0.97	0.31 (0.21–0.48)	0.35 (0.21–0.58)	0.29	0.25 (0.19–0.52)	0.27 (0.18–0.46)	0.93

HDER indicates high‐dose edoxaban regimen (60 mg); HDER‐DR, HDER dose reduction (30 mg); LDER, low‐dose edoxaban regimen (30 mg); LDER‐DR, LDER dose reduction (15 mg).

*P<0.05 is significant for difference in median trough levels by Wilcoxon rank‐sum test.